clinical trial · NCT04536077

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Washington University School of Medicine →·phase2·terminated·n = 16

Pancreatic CancerCancer of the PancreasPancreas CancerCDX-301CDX-1140Research blood draw

brief summary

The central hypothesis is that the addition of CDX-301 to CDX-1140 radically improves anti-tumor immunity in patients with pancreatic ductal adenocarcinoma.

started

Aug 13, 2021

primary completion

Nov 21, 2023

completion

Nov 21, 2023

last updated

Oct 8, 2024

official title

Testing the Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol